Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2000 | 1 |
2001 | 2 |
2002 | 1 |
2003 | 1 |
2008 | 1 |
2009 | 1 |
2010 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Bryostatin-1: a novel PKC inhibitor in clinical development.
Cancer Invest. 2003;21(6):924-36. doi: 10.1081/cnv-120025095.
Cancer Invest. 2003.
PMID: 14735696
Review.
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah MA, Schwartz GK.
Shah MA, et al.
Clin Cancer Res. 2001 Aug;7(8):2168-81.
Clin Cancer Res. 2001.
PMID: 11489790
Review.
Item in Clipboard
Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A, Schwartz GK.
Kaubisch A, et al.
Cancer J. 2000 Jul-Aug;6(4):192-212.
Cancer J. 2000.
PMID: 11038138
Review.
Item in Clipboard
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D.
Schwartz GK, et al.
J Clin Oncol. 2002 Apr 15;20(8):2157-70. doi: 10.1200/JCO.2002.08.080.
J Clin Oncol. 2002.
PMID: 11956278
Clinical Trial.
Item in Clipboard
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gönen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ.
Goteti K, et al.
Cancer Chemother Pharmacol. 2010 Jul;66(2):245-54. doi: 10.1007/s00280-009-1153-z. Epub 2009 Oct 16.
Cancer Chemother Pharmacol. 2010.
PMID: 19841922
Item in Clipboard
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Jung CP, Motwani MV, Schwartz GK.
Jung CP, et al.
Clin Cancer Res. 2001 Aug;7(8):2527-36.
Clin Cancer Res. 2001.
PMID: 11489836
Item in Clipboard
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Ambrosini G, Seelman SL, Qin LX, Schwartz GK.
Ambrosini G, et al.
Cancer Res. 2008 Apr 1;68(7):2312-20. doi: 10.1158/0008-5472.CAN-07-2395.
Cancer Res. 2008.
PMID: 18381438
Item in Clipboard
Cite
Cite